

FDA Turns Up the Heat on GLP-1 Dupes Sold “For Research Use Only,” Finds Intended Use Suggests Otherwise

[Donnelly L. McDowell](#), [Cristina Ferretti](#)

April 24, 2026

In this episode, we unpack the FDA’s latest enforcement wave targeting GLP-1 “dupes,” where companies have been marketing unapproved injectable products as “research use only” or “not for human consumption,” while simultaneously providing dosing instructions, testimonials, and other signals of intended human use. The FDA’s message is increasingly clear: it will look beyond disclaimers and focus on how products are actually marketed and used, treating misleading labeling as a potential violation of drug laws and a serious public health risk as scrutiny of compounded and unapproved GLP-1 products continues to intensify.

Hosted by Simone Roach. Based on a blog post by [Donnelly L. McDowell](#) and [Cristina Ferretti](#).